Last reviewed · How we verify
290-800 nm sunscreen
The 290-800 nm sunscreen, developed by Universidad Autonoma de San Luis Potosí, is currently marketed but lacks detailed revenue data. A key strength is the protection of its core composition, secured by a patent expiring in 2028. The primary risk lies in the lack of disclosed clinical trial results and primary indication, which may limit its competitive positioning against established players.
At a glance
| Generic name | 290-800 nm sunscreen |
|---|---|
| Also known as | Benzophenone-3, Octinoxate, Octocrylene, Titanium Dioxide, Zinc Oxide |
| Sponsor | Universidad Autonoma de San Luis Potosí |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 290-800 nm sunscreen CI brief — competitive landscape report
- 290-800 nm sunscreen updates RSS · CI watch RSS
- Universidad Autonoma de San Luis Potosí portfolio CI